US Bill For CBD Supplement Path Draws Mixed Industry Response
Executive Summary
Four major trade organizations applauded the introduction of HR 8179, which would remove statutory impediments to CBD’s lawful use in dietary supplements, subjecting CBD to the same requirements in place for any new dietary ingredient. The Natural Products Association, on the other hand, is calling the bill a misstep.
You may also be interested in...
If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off
At FDLI annual meeting, attorneys cast doubt on CBD rules outlook. Paul Joseph says regulations are at least a year away while Jonathan Havens doubts FDA is even working on regulations, including GMPs, because it is still asking industry for specific safety details.
Lawful Use Of Cannabidiols In Supplements ‘Different Than The Rest’ Of US FDA Regulations?
CFSAN regulatory affairs chief Douglas Stearn says a regulatory pathway wouldn’t be an open door for CBD-containing food and supplements due to concerns about the ingredients’ safety. Legislation from Congress might "do something with CBD that’s different than the rest of the Food, Drug and Cosmetic Act," he says.
Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work
Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: